Historical Valuation
Moderna Inc (MRNA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.29 is considered Undervalued compared with the five-year average of -1.86. The fair price of Moderna Inc (MRNA) is between 254.85 to 278.69 according to relative valuation methord. Compared to the current price of 34.30 USD , Moderna Inc is Undervalued By 86.54%.
Relative Value
Fair Zone
254.85-278.69
Current Price：34.30
86.54%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Moderna Inc (MRNA) has a current Price-to-Book (P/B) ratio of 1.29. Compared to its 3-year average P/B ratio of 2.21 , the current P/B ratio is approximately -41.46% higher. Relative to its 5-year average P/B ratio of 5.79, the current P/B ratio is about -77.65% higher. Moderna Inc (MRNA) has a Forward Free Cash Flow (FCF) yield of approximately -22.00%. Compared to its 3-year average FCF yield of -15.08%, the current FCF yield is approximately 45.89% lower. Relative to its 5-year average FCF yield of -4.13% , the current FCF yield is about 432.89% lower.
P/B
Median3y
2.21
Median5y
5.79
FCF Yield
Median3y
-15.08
Median5y
-4.13
Competitors Valuation Multiple
AI Analysis for MRNA
The average P/S ratio for MRNA competitors is 191.13, providing a benchmark for relative valuation. Moderna Inc Corp (MRNA.O) exhibits a P/S ratio of 6.29, which is -96.71% above the industry average. Given its robust revenue growth of -45.44%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MRNA
1Y
3Y
5Y
Market capitalization of MRNA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MRNA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MRNA currently overvalued or undervalued?
Moderna Inc (MRNA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.29 is considered Undervalued compared with the five-year average of -1.86. The fair price of Moderna Inc (MRNA) is between 254.85 to 278.69 according to relative valuation methord. Compared to the current price of 34.30 USD , Moderna Inc is Undervalued By 86.54% .
What is Moderna Inc (MRNA) fair value?
MRNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Moderna Inc (MRNA) is between 254.85 to 278.69 according to relative valuation methord.
How does MRNA's valuation metrics compare to the industry average?
The average P/S ratio for MRNA's competitors is 191.13, providing a benchmark for relative valuation. Moderna Inc Corp (MRNA) exhibits a P/S ratio of 6.29, which is -96.71% above the industry average. Given its robust revenue growth of -45.44%, this premium appears unsustainable.
What is the current P/B ratio for Moderna Inc (MRNA) as of Jan 10 2026?
As of Jan 10 2026, Moderna Inc (MRNA) has a P/B ratio of 1.29. This indicates that the market values MRNA at 1.29 times its book value.
What is the current FCF Yield for Moderna Inc (MRNA) as of Jan 10 2026?
As of Jan 10 2026, Moderna Inc (MRNA) has a FCF Yield of -22.00%. This means that for every dollar of Moderna Inc’s market capitalization, the company generates -22.00 cents in free cash flow.
What is the current Forward P/E ratio for Moderna Inc (MRNA) as of Jan 10 2026?
As of Jan 10 2026, Moderna Inc (MRNA) has a Forward P/E ratio of -3.67. This means the market is willing to pay $-3.67 for every dollar of Moderna Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Moderna Inc (MRNA) as of Jan 10 2026?
As of Jan 10 2026, Moderna Inc (MRNA) has a Forward P/S ratio of 6.29. This means the market is valuing MRNA at $6.29 for every dollar of expected revenue over the next 12 months.